Salient Features: Molnupiravir (Now approved in India) in unvaccinated adult outpatients with mild-to-moderate COVID-19, reduced rates of hospitalization or all-cause mortality by 30% (N Engl J Med 2021 Dec 16J. The dose is 800 mg (four 200-mg capsules) twice a for 5 days.
Not approved for children below 18 years and pregnant women). Paxlovid (Not yet approved in India)is administered with ritonavir reduced rates of hospitalization or all-cause death by almost 90% among unvaccinated high-risk adult outpatients Good data now support the efficacy of the parenteral antiviral remdesivir in at-risk outpatients with COVID-19 (N Engl J Med 2021 Dec 22;
